Using the TRAMPC1 PCa model, the authors demonstrated that FAO inhibition with ranolazine decreases Tim3 content in CD8+ tumor-infiltrating T cells, increases macrophages, and decreases blood myeloid immunosuppressive monocytes, suggesting that targeting FAO stimulates anti-cancer immunity (118). This evidence concerns the gene CD8A and cancer.